Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 18/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10143379 | 0.98 | PIK3CG (0.63) | PIK3CGPIK3CDPIK3CAPRKDCFGFR1 | |
| SCHEMBL19355940 | 0.92 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CAPRKDCFGFR1 | |
| SCHEMBL10142537 | 0.91 | PIK3CG (0.58) | PIK3CGPIK3CDPIK3CAPRKDCFGFR1 | |
| SCHEMBL10142143 | 0.91 | PIK3CG (0.64) | PIK3CGPIK3CDPIK3CAPRKDC | |
| SCHEMBL10142139 | 0.91 | PIK3CG (0.63) | PIK3CGPIK3CDPIK3CAPRKDCFGFR1 | |
| SCHEMBL10174161 | 0.91 | PIK3CG (0.56) | PIK3CGPIK3CDPIK3CAPRKDCFGFR1 | |
| SCHEMBL10142777 | 0.90 | PIK3CG (0.66) | PIK3CGPIK3CDPIK3CAPRKDCFGFR1 | |
| SCHEMBL10142370 | 0.90 | PIK3CG (0.73) | PIK3CGPIK3CDPIK3CAPRKDCFGFR1 | |
| SCHEMBL10142553 | 0.89 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPRKDCFGFR1 | |
| SCHEMBL15032026 | 0.88 | PIK3CG (0.67) | PIK3CGPIK3CDPIK3CAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808739-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3309152-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2516417-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | PIK3CG 4/4885PIK3CD 1/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.